Azathioprine as a single immunosuppressive drug in the treatment of myasthenia gravis.

Acta neurologica Pub Date : 1993-04-01
V Cosi, M Lombardi, A Erbetta, G Piccolo
{"title":"Azathioprine as a single immunosuppressive drug in the treatment of myasthenia gravis.","authors":"V Cosi,&nbsp;M Lombardi,&nbsp;A Erbetta,&nbsp;G Piccolo","doi":"","DOIUrl":null,"url":null,"abstract":"<p><p>We retrospectively evaluated results obtained from azathioprine (AZA) treatment on a selected sample of 40 patients affected by autoimmune myasthenia gravis (MG). Patients received AZA as a single immunosuppressive drug for at least 2 years. Twenty out of 40 patients received also a one-month course of cyclophosphamide (CP) before starting AZA. All patients started immunosuppressive treatment out of myasthenic crisis. After 3, 12 and 24 months of AZA treatment, 82.5%, 92.5% and 97.5% of the patients respectively showed improvement in functional state, disappearance of bulbar involvement, or both. The impressive percentage of short-term positive results did not seem influenced by pre-treatment by CP. Side effects included only minor and transitory gastrointestinal symptoms and reversible cytopenia. Although the patient population was either particularly suitable for AZA treatment or candidate to a better response, our data suggest that AZA might also have good short term effects in a subgroup of MG patients.</p>","PeriodicalId":6970,"journal":{"name":"Acta neurologica","volume":"15 2","pages":"123-31"},"PeriodicalIF":0.0000,"publicationDate":"1993-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Acta neurologica","FirstCategoryId":"1085","ListUrlMain":"","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

Abstract

We retrospectively evaluated results obtained from azathioprine (AZA) treatment on a selected sample of 40 patients affected by autoimmune myasthenia gravis (MG). Patients received AZA as a single immunosuppressive drug for at least 2 years. Twenty out of 40 patients received also a one-month course of cyclophosphamide (CP) before starting AZA. All patients started immunosuppressive treatment out of myasthenic crisis. After 3, 12 and 24 months of AZA treatment, 82.5%, 92.5% and 97.5% of the patients respectively showed improvement in functional state, disappearance of bulbar involvement, or both. The impressive percentage of short-term positive results did not seem influenced by pre-treatment by CP. Side effects included only minor and transitory gastrointestinal symptoms and reversible cytopenia. Although the patient population was either particularly suitable for AZA treatment or candidate to a better response, our data suggest that AZA might also have good short term effects in a subgroup of MG patients.

硫唑嘌呤作为单一免疫抑制药物治疗重症肌无力。
我们回顾性评估了40例自身免疫性重症肌无力(MG)患者接受硫唑嘌呤(AZA)治疗的结果。患者接受AZA作为单一免疫抑制药物至少2年。40例患者中有20例在开始AZA治疗前也接受了一个月的环磷酰胺疗程。所有患者均因肌无力危象开始免疫抑制治疗。治疗3个月、12个月和24个月后,82.5%、92.5%和97.5%的患者功能状态改善、受累球消失或两者兼而有之。令人印象深刻的短期阳性结果百分比似乎不受CP预处理的影响。副作用仅包括轻微和短暂的胃肠道症状和可逆性细胞减少症。虽然患者群体特别适合AZA治疗或候选更好的反应,但我们的数据表明,AZA在MG患者亚组中也可能具有良好的短期效果。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信